We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
-6.57%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$992B
AUM Growth
-$120B
Cap. Flow
-$16.9B
Cap. Flow %
-1.7%
Top 10 Hldgs %
27.94%
Holding
3,085
New
108
Increased
1,637
Reduced
1,059
Closed
107

Top Buys

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$4.45B
2
JPM icon
JPMorgan Chase
JPM
+$2.22B
3
TEAM icon
Atlassian
TEAM
+$2.08B
4
NVDA icon
NVIDIA
NVDA
+$1.81B
5
AAPL icon
Apple
AAPL
+$1.67B

Sector Composition

Rank Sector Weight
1 Technology 26.79%
2 Healthcare 17.19%
3 Consumer Discretionary 15.16%
4 Financials 10.74%
5 Communication Services 10.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CKPT
2826
DELISTED
Checkpoint Therapeutics
CKPT
$104K ﹤0.01%
+5,900
New +$127K
HROW icon
2827
Harrow
HROW
$1.45B
$103K ﹤0.01%
15,100
YEXT icon
2828
Yext
YEXT
$587M
$102K ﹤0.01%
14,846
+3,272
+28% +$25K
TCRR
2829
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$102K ﹤0.01%
36,781
+500
+1% +$1.57K
BLUE
2830
DELISTED
bluebird bio
BLUE
$100K ﹤0.01%
1,034
+75
+8% +$9.9K
SCPX
2831
DELISTED
Scorpius Holdings, Inc.
SCPX
$100K ﹤0.01%
8
BRMK
2832
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$100K ﹤0.01%
+11,554
New +$103K
PZN
2833
DELISTED
Pzena Investment Management, Inc. Class A
PZN
$100K ﹤0.01%
12,439
+300
+2% +$2.74K
REV
2834
DELISTED
Revlon, Inc.
REV
$100K ﹤0.01%
+12,366
New +$118K
LMACA
2835
DELISTED
Liberty Media Acquisition Corporation Series A Common Stock
LMACA
$99K ﹤0.01%
10,040
OCUL icon
2836
Ocular Therapeutix
OCUL
$2.23B
$98K ﹤0.01%
19,741
+6,481
+49% +$35.9K
WVVI icon
2837
Willamette Valley Vineyards
WVVI
$11.8M
$98K ﹤0.01%
10,850
RCEL icon
2838
Avita Medical
RCEL
$253M
$96K ﹤0.01%
+11,290
New +$104K
SYRS
2839
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$96K ﹤0.01%
8,088
-2,040
-20% -$36.5K
FRO icon
2840
Frontline
FRO
$9.02B
$95K ﹤0.01%
+10,840
New +$85.9K
UAVS icon
2841
AgEagle Aerial Systems
UAVS
$62.1M
$95K ﹤0.01%
80
+54
+208% +$63.8K
INSG icon
2842
Inseego
INSG
$77.5M
$94K ﹤0.01%
2,312
+630
+37% +$28.8K
LCTX icon
2843
Lineage Cell Therapeutics
LCTX
$268M
$94K ﹤0.01%
61,091
+2,700
+5% +$4.19K
OMIC
2844
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$94K ﹤0.01%
495
+112
+29% +$25.9K
LYTS icon
2845
LSI Industries
LYTS
$906M
$93K ﹤0.01%
15,525
SEAC
2846
DELISTED
Seachange International Inc
SEAC
$93K ﹤0.01%
4,095
SFT
2847
DELISTED
Shift Technologies, Inc. Class A Common Stock
SFT
$93K ﹤0.01%
4,237
+1,783
+73% +$39.6K
QUMU
2848
DELISTED
Qumu Corp.
QUMU
$93K ﹤0.01%
52,750
+2,500
+5% +$4.67K
LU icon
2849
Lufax Holding
LU
$1.31B
$92K ﹤0.01%
+4,150
New +$91.4K
STTK icon
2850
Shattuck Labs
STTK
$748M
$92K ﹤0.01%
21,616
+500
+2% +$2.84K

Similar funds

T. Rowe Price Associates's Q1 2022 Portfolio in Review

As of Q1 2022, T. Rowe Price Associates held 3,085 positions worth $992B, down 11% from $1.11T the previous quarter. Its ten largest holdings account for 28% of the portfolio.

T. Rowe Price Associates's Q1 2022 filing shows 108 new, 1,637 increased, 1,059 reduced and 107 closed positions. Its largest new stake was Nutrien: 6,143,560 shares worth $639M. The largest sale was Alphabet (Google) Class C, an estimated $3.24B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q1 2022 buy was Nutrien: 6,143,560 shares worth $639M.
  • T. Rowe Price Associates added most to Tesla in Q1 2022, an estimated $4.45B increase.
  • T. Rowe Price Associates's biggest Q1 2022 reduction was Alphabet (Google) Class C, cutting an estimated $3.24B.
  • T. Rowe Price Associates fully exited Xilinx Inc in Q1 2022, selling an estimated $481M.
  • T. Rowe Price Associates's ten largest holdings make up 28% of its $992B portfolio in Q1 2022.
  • T. Rowe Price Associates opened 108 new positions and closed 107 in Q1 2022.
  • T. Rowe Price Associates's portfolio value fell 11% quarter-over-quarter to $992B.

Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.